Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL +3.64%8 Equity-to-Asset is 0.87 as of Jun. 2026, which is 691% above its 10-year median of 0.11. GuruFocus rates ANL with a GF Score™ of 8/100. The stock has 8 warning signs investors should review. Among 1,412 Biotechnology companies, Adlai Nortye ranks better than 76.84% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Adlai Nortye's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $214.83 Mil. Adlai Nortye's Total Assets for the quarter that ended in Jun. 2026 was $248.36 Mil.
Therefore, Adlai Nortye's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.87.
The historical rank and industry rank for Adlai Nortye's Equity-to-Asset or its related term are showing as below:
ANL'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.78 Med: 0.11 Max: 0.87
Current: 0.87
During the past 5 years, the highest Equity to Asset Ratio of Adlai Nortye was 0.87. The lowest was -4.78. And the median was 0.11.
ANL's Equity-to-Asset is ranked better than 76.84% of 1412
companies
in the Biotechnology industry
Industry Median: 0.69
vs ANL: 0.87
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Adlai Nortye Equity-to-Asset Related Terms
Adlai Nortye Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs TBPH, ACRS, ATTO: Equity-to-Asset Comparison
For the Biotechnology subindustry, Adlai Nortye's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Adlai Nortye's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a Equity-to-Asset of 0.87 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Adlai Nortye and its competitors. This is 691% above median its historical median of 0.11. According to the industry distribution chart, Adlai Nortye ranks #327 out of 1412 companies in the Biotechnology industry, placing it in the top 23.2%.
Is Adlai Nortye's Equity-to-Asset too high?
Adlai Nortye's current Equity-to-Asset of 0.87 is 691% above median its 10-year median of 0.11. The Biotechnology industry median Equity-to-Asset is 0.69. Adlai Nortye's value of 0.87 is 26.1% above this industry median. Based on the distribution chart, Adlai Nortye ranks #327 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Adlai Nortye has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's Equity-to-Asset compare to TBPH and ACRS?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #327 out of 1412 companies for Equity-to-Asset. This places Adlai Nortye in the top 23% of its industry — outperforming the majority of peers. The industry median Equity-to-Asset is 0.69. Adlai Nortye's value of 0.87 is 26.1% above this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 0.69, Adlai Nortye has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.69, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current Equity-to-Asset of 0.87 is 26.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Equity-to-Asset is 0.87, which is 691% above median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Equity-to-Asset of 0.87. The current Equity-to-Asset is 0.87, which is 691% above median its 10-year median of 0.11 and 26.1% above the Biotechnology industry median of 0.69. Adlai Nortye's overall GF Score™ is 8/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Equity-to-Asset is 0.87 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
8GF Score
Get the complete analysis for ANL
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
